CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma (PMLBCL)

Study Overview
=================
Brief Summary
-----------------
This is a retrospective, multicenter study designed to collect data on the diagnostic, therapeutic management and outcome of patients diagnosed with primary mediastinal lymphoma who have progressed or relapsed with central nervous system (CNS) involvement. Through this study, an international data set from 6 different countries will be collected on clinical factors, anti-lymphoma therapy administered alone or in conjunction with CNS prophylaxis, re-biopsy site information when available, dose intensity of lymphoma therapy received at recurrence, and patient outcome. In addition, to better characterize the pathologic features of this rare entity, a central pathologic review of the initial diagnosis and, if available, histologic confirmation of recurrence will be performed.

Official Title
-----------------
Retrospective Multicenter International Study on Prognostic Factors, Management And Outcome Of Primary Mediastinal Large B-Cell Lymphoma (PMLBCL) Patients With Central Nervous System (Cns) Involvement.

Conditions
-----------------
Primary Mediastinal Large B-cell Lymphoma (PMBCL)

Intervention / Treatment
-----------------
* Other: DISEASE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: To be eligible for inclusion each patient must fulfil all of the following criteria: Histologically confirmed diagnosis of Primary Mediastinal Large B Cell Lymphoma (PMLBCL) according WHO Classification Had a recurrence/progression with Central Nervous System (CNS) involvement Availability of details on clinical presentation, treatment details and outcome Availability of details on pathological data for central review Age ≥18 years Exclusion Criteria: Patients with CNS lymphoma other than PMLBCL subtype

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: DISEASE|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PT CHARACTERISTICS | to describe the PMLBCL characteristics at diagnosis and at CNS relapse ( first relapse or second and subsequent recurrences) and the treatment received | 2003-2020 | 
| CNS RELAPSE | to describe the median time to CNS relapse | 2003-2020 | 
| PROGNOSTIC FACTORS | to define prognostic factors of outcome of CNS relapse in PMLBCL patients | 2003-2020 | 
| TREATMENT STRATEGY | to correlate treatment strategy with survival end-points | 2003-2020 | 
| PFS | to evaluate the Progression Free Survical ( PFS) after CNS events | 2003-2020 | 
| OS | to evaluate Overall Survival ( OS) after CNS relapse | 2003-2020 | 
| MOLECULAR DIAGNOSTIC | to central pathological reviewed the initial diagnosis and the relapse and to correlate biological and molecular factors with CNS recurrence | 2003-2020 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PMLBCL, CNS